Therapeutic Inertia in Uncontrolled Hypertension: A Mixed-Methods Analysis of Physician, Patient and System-Level Barriers in Family Medicine

Hypertension remains one of the leading global contributors to cardiovascular morbidity and mortality, accounting for a substantial proportion of preventable adverse outcomes. Although lifestyle modification plays an important role, pharmacological therapy remains the cornerstone of effective blood pressure control for most patients. However, despite the availability of clear evidence-based guidelines and effective antihypertensive agents, blood pressure control rates remain suboptimal in real-world clinical practice, particularly in primary care settings.

Therapeutic inertia—commonly defined as failure to initiate or intensify treatment when therapeutic goals are unmet—has emerged as a key contributor to persistent uncontrolled hypertension. Numerous studies across diverse healthcare systems have demonstrated that treatment escalation is frequently delayed or omitted, resulting in prolonged exposure to elevated blood pressure and increased cardiovascular risk.

The causes of therapeutic inertia are multifactorial. Physician-related factors include concerns about adverse drug effects, uncertainty regarding guideline thresholds, competing clinical priorities, and limited consultation time. Patient-related factors such as fear of side effects, low health literacy, poor adherence, and asymptomatic perception of disease further complicate treatment decisions. In addition, system-level barriers—fragmented care, inadequate follow-up mechanisms, and high patient volumes—may reinforce inertia in routine practice.

Emerging evidence suggests that therapeutic inertia should not be viewed solely as passive non-action, but rather as a modifiable process influenced by treatment strategies and healthcare structures. Early use of combination therapy has been shown to improve blood pressure control and reduce inertia compared with stepwise monotherapy; however, such approaches remain underutilized in primary care.

While most existing studies have quantified the prevalence of therapeutic inertia, fewer have explored the contextual and behavioral factors underlying clinical decision-making. Mixed-methods research offers a comprehensive approach by integrating quantitative outcomes with qualitative insights from physicians and patients. This study therefore aimed to assess the prevalence of therapeutic inertia in uncontrolled hypertension and to explore the physician-, patient-, and system-level barriers contributing to delayed treatment intensification in a family medicine setting.

Participant Characteristics

A total of 312 patients were included in the quantitative analysis, with a mean age of 58.4 ± 11.6 years; 54.8% were male. Most patients had at least one comorbidity, most commonly type 2 diabetes mellitus and dyslipidemia. Eighteen family physicians and twenty-two patients participated in the qualitative interviews.

Table 1. Baseline Characteristics of the Study Population (N = 312)

Prevalence of Therapeutic Inertia

Therapeutic inertia was identified in 46.8% of patients with uncontrolled hypertension. Patients experiencing therapeutic inertia had higher systolic and diastolic blood pressure levels and were less likely to achieve subsequent blood pressure control compared with patients whose treatment was intensified.

Treatment Patterns and Outcomes

Monotherapy predominated among patients with therapeutic inertia, whereas combination therapy was more frequently prescribed in patients undergoing treatment intensification. Treatment intensification was associated with significantly greater reductions in systolic and diastolic blood pressure and higher rates of blood pressure control.

Table 2. Antihypertensive Treatment Patterns and Clinical Response

Qualitative Findings

Three major themes emerged:

1. Physician-related barriers: concerns about adverse effects, polypharmacy in older patients, uncertainty regarding adherence, and limited consultation time.
2. Patient-related barriers: fear of medication escalation, misconceptions regarding asymptomatic disease, and inadequate understanding of long-term cardiovascular risk.
3. System-level barriers: fragmented care, delayed follow-up, and limited access to home blood pressure monitoring.

Table 3. Key Themes and Representative Findings From Qualitative Analysis

Figure 1. Proportion of Patients Experiencing Therapeutic Inertia According to Age Group and Treatment Regimen 

Figure 2. Comparison of Blood Pressure Reduction Between Patients With and Without Therapeutic Inertia

Figure 3. Conceptual Framework Illustrating Physician-, Patient-, and System-Level Contributors to Therapeutic Inertia

This mixed-methods study confirms that therapeutic inertia remains a leading cause of suboptimal blood pressure control in family medicine. Nearly half of patients with uncontrolled hypertension did not undergo treatment intensification despite repeated elevated readings. These findings align with population-based and primary care studies showing persistent gaps between guideline recommendations and real-world hypertension management (9,10).

Older age, longer hypertension duration, multimorbidity, and treatment with monotherapy were significantly associated with therapeutic inertia. These findings are consistent with prior reports suggesting that clinicians may hesitate to intensify treatment in elderly or complex patients because of concerns regarding adverse effects, frailty, and treatment burden (9,12). While clinically understandable, such caution may unnecessarily prolong exposure to uncontrolled blood pressure and increase cardiovascular risk.

Patients whose therapy was intensified experienced substantially greater blood pressure reductions, highlighting the clinical value of timely treatment adjustment. This supports evidence from large studies demonstrating the superiority of combination therapy and proactive treatment strategies in achieving blood pressure control and preventing resistant hypertension (10,14). However, many patients with therapeutic inertia remained on monotherapy, indicating underuse of evidence-based approaches in routine practice.

Qualitative findings identified physician-related factors as the primary drivers of therapeutic inertia, including concerns about polypharmacy, uncertainty regarding adherence, and limited consultation time. Similar barriers have been reported across diverse healthcare systems, indicating that therapeutic inertia is a global challenge (12). These results support the need for clinician-focused interventions such as decision-support tools and structured follow-up pathways.

Patient-related factors, particularly misperceptions about disease severity and fear of medication escalation, further contributed to resistance to treatment intensification. Many patients equated the absence of symptoms with adequate control, a well-recognized barrier in chronic disease management (13), underscoring the importance of patient education and shared decision-making.

System-level barriers, including limited access to follow-up, fragmented care, and underutilization of home blood pressure monitoring, also played a role. Evidence suggests that self-measured blood pressure monitoring improves treatment decisions and patient engagement in primary care settings (11).

Although brachial blood pressure measurement remains standard, emerging evidence indicates that central aortic pressure may offer additional prognostic value in treated hypertension (15). While not assessed in this study, its future integration may help reduce clinical uncertainty and support more timely treatment intensification.

Therapeutic inertia is a major contributor to persistently uncontrolled hypertension in family medicine practice. Addressing this challenge requires coordinated interventions targeting clinician decision-making, patient education and engagement, and healthcare system inefficiencies. Reducing therapeutic inertia has the potential to substantially improve blood pressure control and lower long-term cardiovascular risk in primary care populations.

1.           Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223-237. doi:10.1038/s41581-019-0244-2

2.           Zhou B, Carrillo-Larco RM, Danaei G, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019. Lancet. 2021;398(10304):957-980. doi:10.1016/S0140-6736(21)01330-1

3.           Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension. 2018;71(6):e13-e115. doi:10.1161/HYP.0000000000000065

4.           Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. doi:10.1093/eurheartj/ehy339

5.           Burnier M, Egan BM. Adherence in hypertension. Circ Res. 2019;124(7):1124-1140. doi:10.1161/CIRCRESAHA.118.313220

6.           Okonofua EC, Simpson KN, Jesri A, et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006;47(3):345-351. doi:10.1161/01.HYP.0000200702.76436.4b

7.           Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001;135(9):825-834. doi:10.7326/0003-4819-135-9-200111060-00012

8.           Lebeau JP, Cadwallader JS, Aubin-Auger I, et al. The concept and definition of therapeutic inertia in hypertension. Br J Gen Pract. 2014;64(628):e787-e795. doi:10.3399/bjgp14X682981

9.           Crowley MJ, Powers BJ, Olsen MK, et al. The effect of therapeutic inertia on hypertension control. Hypertension. 2016;67(2):314-321. doi:10.1161/HYPERTENSIONAHA.115.06342

10.         Egan BM, Li J, Hutchison FN, Ferdinand KC. Hypertension in the United States, 1999–2012. J Am Heart Assoc. 2014;3(3):e001032. doi:10.1161/JAHA.114.001032

11.         Tucker KL, Sheppard JP, Stevens R, et al. Self-monitoring of blood pressure in hypertension. Lancet. 2017;389(10078):959-967. doi:10.1016/S0140-6736(16)31776-4

12.         Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2017;73(5):691-705. doi:10.1111/j.1365-2125.2012.04167.x

13.         Abegaz TM, Shehab A, Gebreyohannes EA, et al. Nonadherence to antihypertensive drugs. Medicine (Baltimore). 2017;96(4):e5641. doi:10.1097/MD.0000000000005641

14.         Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in hypertension. Am J Med. 2009;122(3):290-300. doi:10.1016/j.amjmed.2008.09.038

15.         Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence. J Hypertens. 2016;34(4):613-622. doi:10.1097/HJH.0000000000000855

16.         Khatib R, Schwalm JD, Yusuf S, et al. Patient and healthcare provider barriers to hypertension awareness and control. Glob Heart. 2014;9(3):311-321. doi:10.1016/j.gheart.2014.05.002

17.         Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension. Hypertension. 2018;72(5):e53-e90. doi:10.1161/HYP.0000000000000084

18.         Banegas JR, López-García E, Dallongeville J, et al. Achievement of treatment goals for primary prevention of cardiovascular disease. Lancet. 2011;378(9799):1287-1297. doi:10.1016/S0140-6736(11)61536-0

19.         Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;2014(11):CD000011. doi:10.1002/14651858.CD000011.pub4

20.         Muiesan ML, Salvetti M, Paini A, et al. Resistant hypertension and therapeutic inertia. High Blood Press Cardiovasc Prev. 2017;24(2):127-133. doi:10.1007/s40292-017-0202-9

21.         De la Sierra A, Segura J, Banegas JR, et al. Clinical features of resistant hypertension. Hypertension. 2011;57(5):898-902. doi:10.1161/HYPERTENSIONAHA.110.168948

22.         Berra E, Azizi M, Capron A, et al. Evaluation of adherence should become an integral part of assessment of patients with apparently treatment-resistant hypertension. Hypertension. 2016;68(2):297-306. doi:10.1161/HYPERTENSIONAHA.116.07464

23.         Parati G, Stergiou GS, Asmar R, et al. European Society of Hypertension guidelines for blood pressure monitoring. J Hypertens. 2014;32(7):1359-1366. doi:10.1097/HJH.0000000000000221

24.         Kjeldsen SE, Narkiewicz K, Burnier M, et al. Medical inertia in hypertension. J Hypertens. 2018;36(6):1156-1157. doi:10.1097/HJH.0000000000001721

25.         Brouwers S, Sudano I, Kokubo Y, et al. Arterial hypertension. Lancet. 2021;398(10296):249-261. doi:10.1016/S0140-6736(21)00221-6